David L. Bourdet

1.1k total citations
37 papers, 821 citations indexed

About

David L. Bourdet is a scholar working on Oncology, Pharmacology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David L. Bourdet has authored 37 papers receiving a total of 821 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Pharmacology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David L. Bourdet's work include Drug Transport and Resistance Mechanisms (9 papers), Inhalation and Respiratory Drug Delivery (7 papers) and Pharmacogenetics and Drug Metabolism (7 papers). David L. Bourdet is often cited by papers focused on Drug Transport and Resistance Mechanisms (9 papers), Inhalation and Respiratory Drug Delivery (7 papers) and Pharmacogenetics and Drug Metabolism (7 papers). David L. Bourdet collaborates with scholars based in United States, United Kingdom and Switzerland. David L. Bourdet's co-authors include Dhiren R. Thakker, William R. Proctor, John B. Pritchard, Gary M. Pollack, Kim L. R. Brouwer, Pamela R. Tsuruda, Jacqueline A.M. Smith, Patrick Brassil, Kevin DeMent and Jayaprakasam Bolleddula and has published in prestigious journals such as Circulation, Gastroenterology and CHEST Journal.

In The Last Decade

David L. Bourdet

34 papers receiving 796 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David L. Bourdet United States 14 317 194 182 160 114 37 821
Birk Poller Switzerland 20 684 2.2× 254 1.3× 337 1.9× 257 1.6× 97 0.9× 35 1.3k
Rhys Whomsley Belgium 17 153 0.5× 210 1.1× 211 1.2× 244 1.5× 69 0.6× 36 928
Tessa M. Bosch Netherlands 17 411 1.3× 186 1.0× 278 1.5× 164 1.0× 38 0.3× 33 953
Venkatesh Pilla Reddy United States 19 305 1.0× 207 1.1× 325 1.8× 130 0.8× 48 0.4× 56 1.1k
Abhijit Barve United States 14 221 0.7× 74 0.4× 108 0.6× 117 0.7× 57 0.5× 37 663
Kelly Bleasby United States 16 674 2.1× 236 1.2× 240 1.3× 349 2.2× 35 0.3× 21 1.1k
M Zschiesche Germany 12 273 0.9× 190 1.0× 102 0.6× 227 1.4× 165 1.4× 44 764
Gemma L. Dickinson United States 12 246 0.8× 254 1.3× 244 1.3× 122 0.8× 24 0.2× 25 817
Punit H. Marathe United States 15 220 0.7× 158 0.8× 246 1.4× 96 0.6× 35 0.3× 31 854
Catherine Spire France 12 193 0.6× 370 1.9× 341 1.9× 75 0.5× 82 0.7× 14 850

Countries citing papers authored by David L. Bourdet

Since Specialization
Citations

This map shows the geographic impact of David L. Bourdet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Bourdet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Bourdet more than expected).

Fields of papers citing papers by David L. Bourdet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. Bourdet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Bourdet. The network helps show where David L. Bourdet may publish in the future.

Co-authorship network of co-authors of David L. Bourdet

This figure shows the co-authorship network connecting the top 25 collaborators of David L. Bourdet. A scholar is included among the top collaborators of David L. Bourdet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L. Bourdet. David L. Bourdet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kanodia, Jitendra, Hugh Giovinazzo, David L. Bourdet, et al.. (2024). Hepatic Dysfunction Quantified by HepQuant DuO Outperforms Child‐Pugh Classification in Predicting the Pharmacokinetics of Ampreloxetine. Clinical Pharmacology & Therapeutics. 116(1). 186–193. 2 indexed citations
2.
Belperio, John A., Tuan S. Nguyen, David A. Lombardi, et al.. (2023). Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial. BMJ Open Respiratory Research. 10(1). e001627–e001627. 5 indexed citations
3.
Lo, Arthur, Lucy Norcliffe‐Kaufmann, Ross G. Vickery, David L. Bourdet, & Jitendra Kanodia. (2021). Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension. Clinical Autonomic Research. 31(3). 395–403. 6 indexed citations
4.
Hey‐Hadavi, J., Daniel Seekins, Melissa Palmer, et al.. (2021). Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials. Drug Safety. 44(6). 619–634. 20 indexed citations
5.
Kanodia, Jitendra, Arthur Lo, R. Michael Baldwin, Richard Graham, & David L. Bourdet. (2020). Pharmacokinetics of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, in Healthy Subjects and Adults with Attention-Deficit/Hyperactive Disorder or Fibromyalgia Pain. Clinical Pharmacokinetics. 60(1). 121–131. 4 indexed citations
6.
Borin, Marie T., Arthur Lo, Chris N. Barnes, Srikanth Pendyala, & David L. Bourdet. (2019). <p>Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function</p>. International Journal of COPD. Volume 14. 2305–2318. 5 indexed citations
7.
Donohue, James F., Gregory Feldman, Sanjay Sethi, et al.. (2019). Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. Pulmonary Pharmacology & Therapeutics. 57. 101808–101808. 9 indexed citations
8.
Donohue, James F., Gregory Feldman, Sanjay Sethi, et al.. (2018). CARDIOVASCULAR SAFETY OF REVEFENACIN FOR NEBULIZATION: A REVIEW OF RANDOMIZED CONTROLLED TRIAL DATA. CHEST Journal. 154(4). 734A–735A. 2 indexed citations
9.
10.
Proctor, William R., Xin Ming, David L. Bourdet, et al.. (2016). Why Does the Intestine Lack Basolateral Efflux Transporters for Cationic Compounds? A Provocative Hypothesis. Journal of Pharmaceutical Sciences. 105(2). 484–496. 24 indexed citations
11.
Bourdet, David L., et al.. (2014). Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD. European Respiratory Journal. 44(Suppl 58). 1892–1892. 1 indexed citations
12.
Bolleddula, Jayaprakasam, Kevin DeMent, James P. Driscoll, et al.. (2014). Biotransformation and bioactivation reactions of alicyclic amines in drug molecules. Drug Metabolism Reviews. 46(3). 379–419. 60 indexed citations
13.
Bourdet, David L., et al.. (2012). Prediction of Human Serotonin and Norepinephrine Transporter Occupancy of Duloxetine by Pharmacokinetic/Pharmacodynamic Modeling in the Rat. Journal of Pharmacology and Experimental Therapeutics. 341(1). 137–145. 12 indexed citations
14.
Shen, Fei, Jacqueline A.M. Smith, Ray Chang, et al.. (2011). 5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment. Neuropharmacology. 61(1-2). 69–79. 56 indexed citations
15.
Vickery, R., et al.. (2011). Pharmacokinetics and constipation relieving effects of TD-1211 in patients with opioid-induced constipation. Journal of Pain. 12(4). P59–P59. 1 indexed citations
16.
Kikuchi, Ryota, Matthew F. McCown, Pamela F. Olson, et al.. (2010). Effect of Hepatitis C Virus Infection on the mRNA Expression of Drug Transporters and Cytochrome P450 Enzymes in Chimeric Mice with Humanized Liver. Drug Metabolism and Disposition. 38(11). 1954–1961. 20 indexed citations
17.
Proctor, William R., David L. Bourdet, & Dhiren R. Thakker. (2008). Mechanisms Underlying Saturable Intestinal Absorption of Metformin. Drug Metabolism and Disposition. 36(8). 1650–1658. 114 indexed citations
18.
Tian, Xianbin, David L. Bourdet, Richard Ho, et al.. (2006). Ritonavir, Saquinavir, and Efavirenz, but Not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes. Journal of Pharmacology and Experimental Therapeutics. 318(3). 1068–1075. 79 indexed citations
19.
20.
Bourdet, David L., John B. Pritchard, & Dhiren R. Thakker. (2005). Differential Substrate and Inhibitory Activities of Ranitidine and Famotidine toward Human Organic Cation Transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). Journal of Pharmacology and Experimental Therapeutics. 315(3). 1288–1297. 91 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Birk Poller Breakdown of academic impact, for papers by Rhys Whomsley Breakdown of academic impact, for papers by Tessa M. Bosch Breakdown of academic impact, for papers by Venkatesh Pilla Reddy Breakdown of academic impact, for papers by Abhijit Barve Breakdown of academic impact, for papers by Kelly Bleasby Breakdown of academic impact, for papers by M Zschiesche Breakdown of academic impact, for papers by Gemma L. Dickinson Breakdown of academic impact, for papers by Punit H. Marathe Breakdown of academic impact, for papers by Catherine Spire
Rankless by CCL
2026